• USAID FY18 Tuberculosis Report to Congress: Accelerating Action to End TB

    Learn More
  • USAID Global Accelerator to End Tuberculosis: Partnership Statements

    Learn More
  • U.S. Government Achieves 2018 TB Research and Development Funding Target

    Learn More
  • USAID announces the TB Local Organizations Network Annual Program Statement as a key component of the Global Accelerator to End Tuberculosis.

    Learn More
  • To accelerate action on TB, USAID has announced an innovative model, “The Global Accelerator to End Tuberculosis.”

    Learn More
  • The U.S. Government Departments and Agencies charged with implementing the National Action Plan for Combating Multidrug-Resistant Tuberculosis continue to make notable progress towards achieving the Plan's established milestones.

    Learn More
  • As the lead U.S. Government agency for global TB care, USAID works with partners to reach every person with TB, cure those in need of treatment and prevent new TB infections.

    Learn More

At USAID, we focus our investments on strengthening national TB strategies and programs through bilateral programs in priority countries with high rates of TB, drug-resistant TB and HIV-associated TB.

10 million
new cases of TB (estimated, range, 9.0–11.1 million)
1.5 million
TB deaths (range, 1.3–1.6 million)
new drug-resistant TB cases (estimated)
drug-resistant TB cases on treatment

The U.S. Agency for International Development (USAID) supports high-quality screening, diagnosis and treatment services for millions of people affected by TB and multidrug-resistant tuberculosis (MDR-TB). In Fiscal Year 2018, with investments of $265 million focused primarily in 23 countries with bilateral TB funds, the U.S. Government achieved the following results in collaboration with each country's National TB Program:



Countries with bilateral programs


Countries received technical assistance


TB cases detected


Increase in case notifications


Treatment Success Rate


Individuals with DR-TB started on appropriate treatment


GeneXpert cartridges procured under concessional pricing (cumulative)


Countries that used the Bedaquiline Donation Program (cumulative)


Health workers trained


Countries completed drug-resistance surveys (cumulative)


Completed TB prevalence surveys (cumulative)


Research studies supported that focused on new treatment regimen

USAID's investments contributed to an estimated 58 million lives saved from 2000-2018, including people co-infected with HIV/AIDS.


What We Do

USAID works with partner governments to:

  • Prevent TB transmission and renew efforts to find the missing TB cases
  • Strengthen the capacity of national TB programs
  • Build country capacity to use existing resources and to turn evidence into policy
  • Expand the development of new TB diagnostics, drugs and vaccines

Last updated: January 16, 2020

Share This Page